Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
1996-11-7
|
pubmed:abstractText |
Distinct forms of graft-vs-host disease (GVHD) occur in (C57B1/6 x DBA/2)F1 (BDF1) mice inoculated with either C57B1/6 or DBA/2 parental spleen cells, and it has been suggested that this reflects differential activation of CD4+ Th cell subsets. Transfer of B6 cells produces an acute GVHD, during which an early period of lymphoid hyperplasia precedes immunosuppression, weight loss, and mortality, and a Th1 pattern of cytokines is produced. Conversely, transfer of DBA/2 cells induces a chronic GVHD, in which no weight loss or mortality is observed, but an autoimmune, SLE-like GVHD develops in association with a Th2 pattern of cytokines. Recent work indicates that IL-12 plays a central role in the polarization of Th cell-dependent responses, and here we have examined its role in polarizing GVHD, by administering or depleting IL-12 during the afferent phase of both the acute and chronic forms of GVHD in BDF1 mice. In vivo neutralization of endogenous IL-12 ameliorated acute GVHD, in association with reduced splenic NK cell activity, IFN-gamma production, immunosuppression, weight loss, and mortality. Conversely, administration of exogenous murine rIL-12 exacerbates this disease and converts the chronic GVHD into a lethal acute GVHD-like syndrome. These results indicate that IL-12 plays an important role in the development of acute, but not chronic, GVHD and suggest that differential production of IL-12 early in the disease may underlie these distinct outcomes of the GVHD in BDF1 mice injected with different parental cells.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
0022-1767
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
15
|
pubmed:volume |
157
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
689-99
|
pubmed:dateRevised |
2010-8-25
|
pubmed:meshHeading |
pubmed-meshheading:8752918-Acute Disease,
pubmed-meshheading:8752918-Animals,
pubmed-meshheading:8752918-Chronic Disease,
pubmed-meshheading:8752918-Cytotoxicity, Immunologic,
pubmed-meshheading:8752918-Female,
pubmed-meshheading:8752918-Graft vs Host Disease,
pubmed-meshheading:8752918-Immunity, Cellular,
pubmed-meshheading:8752918-Injections, Intraperitoneal,
pubmed-meshheading:8752918-Interleukin-12,
pubmed-meshheading:8752918-Lymphocyte Activation,
pubmed-meshheading:8752918-Mice,
pubmed-meshheading:8752918-Mice, Inbred C57BL,
pubmed-meshheading:8752918-Mice, Inbred DBA
|
pubmed:year |
1996
|
pubmed:articleTitle |
IL-12 is a central mediator of acute graft-versus-host disease in mice.
|
pubmed:affiliation |
Department of Immunology, Western Infirmary, University of Glasgow, Scotland.
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|